We have located links that may give you full text access.
Transcranial Direct Current Stimulation (tDCS) Reduces Nociceptive Behavior in an Orofacial Pain Model.
Journal of Oral Rehabilitation 2018 October 4
BACKGROUND: transcranial Direct Current Stimulation (tDCS) is a non-invasive method of brain stimulation suggested as a therapeutic tool for pain, and is related to reversal of maladaptive plasticity associated with chronic pain.
OBJECTIVES: this study investigated the effect of tDCS, a non-pharmacological therapy, on local mechanical hyperalgesia, and remote thermal hyperalgesia in rats submitted to orofacial inflammatory pain model, by facial von Frey and hot plate tests, respectively. In addition, we evaluated levels of BDNF, NGF, IL-10, and IL-6 in the brainstem and blood serum of these animals at 24h and 7 days after the end of tDCS treatment.
METHODS: rats were subjected to temporomandibular joint pain and treated with tDCS. The animals were divided into control, pain, pain + treatment groups. Mechanical and thermal hyperalgesia were evaluated at baseline, 7 days after administration of complete Freund's adjuvant, and immediately, 24 hours, and 7 days after the tDCS treatment. Neuroimmunomodulators levels were determined by ELISA. Statistical analyses were performed by (GEE)/Bonferroni (behavioral tests), three-way ANOVA/SNK (neurochemical tests), and Kruskal-Wallis (histological analysis).
RESULTS: tDCS reduced mechanical and thermal hyperalgesia (P<0.01). We observed interaction between factors (pain and treatment) increasing brainstem BDNF (P<0.01) and NGF (P<0.05) levels. Furthermore, we found an increase in IL-6 and IL-10 levels in the brainstem at 24h and 7 days after tDCS, respectively.
CONCLUSION: we showed that tDCS reduces thermal and mechanical hyperalgesia induced by orofacial pain until 7 days after treatment. These findings demonstrate that tDCS was effective in the control of orofacial inflammatory pain. This article is protected by copyright. All rights reserved.
OBJECTIVES: this study investigated the effect of tDCS, a non-pharmacological therapy, on local mechanical hyperalgesia, and remote thermal hyperalgesia in rats submitted to orofacial inflammatory pain model, by facial von Frey and hot plate tests, respectively. In addition, we evaluated levels of BDNF, NGF, IL-10, and IL-6 in the brainstem and blood serum of these animals at 24h and 7 days after the end of tDCS treatment.
METHODS: rats were subjected to temporomandibular joint pain and treated with tDCS. The animals were divided into control, pain, pain + treatment groups. Mechanical and thermal hyperalgesia were evaluated at baseline, 7 days after administration of complete Freund's adjuvant, and immediately, 24 hours, and 7 days after the tDCS treatment. Neuroimmunomodulators levels were determined by ELISA. Statistical analyses were performed by (GEE)/Bonferroni (behavioral tests), three-way ANOVA/SNK (neurochemical tests), and Kruskal-Wallis (histological analysis).
RESULTS: tDCS reduced mechanical and thermal hyperalgesia (P<0.01). We observed interaction between factors (pain and treatment) increasing brainstem BDNF (P<0.01) and NGF (P<0.05) levels. Furthermore, we found an increase in IL-6 and IL-10 levels in the brainstem at 24h and 7 days after tDCS, respectively.
CONCLUSION: we showed that tDCS reduces thermal and mechanical hyperalgesia induced by orofacial pain until 7 days after treatment. These findings demonstrate that tDCS was effective in the control of orofacial inflammatory pain. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app